Browse studies
Find your next paid study
2 recruiting studies matching your filters
Phase 1
A Phase 1b, Open-Label Study Of REC-617, A Selective CDK7 Inhibitor, In Patients With Metastatic Or Unresectable RB1-Negative Leiomyosarcoma After Prior Systemic Therapy
To learn if the study drug REC-617 can help to control LMS. The safety of REC-617 will also be studied.
Phase 1bOpen LabelREC-617+2 more
Estimated
~$10 – $6,250
M.D. Anderson Cancer CenterNCT07633756
Phase 1
A Phase 1b Study of HC-7366, an Agonist of ISR With Immunotherapy in Kidney Cancer (SHARK)
To find out if the combination of HC-7366 and nivolumab (with or without ipilimumab) can help to control ccRCC. The
Phase 1bHC-7366SHARK+1 more
Estimated
~$10 – $6,250
M.D. Anderson Cancer CenterNCT07401875